DDX3X Induces Primary EGFR-TKI Resistance Based on Intratumor Heterogeneity in Lung Cancer Cells Harboring EGFR-Activating Mutations

por Nozaki, Koichiro, Kagamu, Hiroshi, Shoji, Satoshi, Igarashi, Natsue, Ohtsubo, Aya, Okajima, Masaaki, Miura, Satoru, Watanabe, Satoshi, Yoshizawa, Hirohisa, Narita, Ichiei
Publicado 2014

Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens

por Kubota, Kaoru, Saito, Mitsue, Aogi, Kenjiro, Sekine, Ikuo, Yoshizawa, Hirohisa, Yanagita, Yasuhiro, Sakai, Hiroshi, Inoue, Kenichi, Kitagawa, Chiyoe, Ogura, Takashi
Publicado 2016

Henoch Schönlein purpura associated with pulmonary adenocarcinoma

por Mifune, Daiki, Watanabe, Satoshi, Kondo, Rie, Wada, Yoko, Moriyama, Hiroshi, Kagamu, Hiroshi, Yoshizawa, Hirohisa, Tetsuka, Takafumi, Matsuyama, Asako, Ito, Kaoru, Narita, Ichiei
Publicado 2011

Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analys...

por Watanabe, Satoshi, Tanaka, Junta, Ota, Takeshi, Kondo, Rie, Tanaka, Hiroshi, Kagamu, Hiroshi, Ichikawa, Kosuke, Koshio, Jun, Baba, Junko, Miyabayashi, Takao, Narita, Ichiei, Yoshizawa, Hirohisa
Publicado 2011

Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q

por Watanabe, Satoshi, Minegishi, Yuji, Yoshizawa, Hirohisa, Maemondo, Makoto, Inoue, Akira, Sugawara, Shunichi, Isobe, Hiroshi, Harada, Masao, Ishii, Yoshiki, Gemma, Akihiko, Hagiwara, Koichi, Kobayashi, Kunihiko
Publicado 2014

A prospective phase II study of multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small cell lung cancer (Niigata Lung Cancer Treatment Group 14...

por Okajima, Masaaki, Miura, Satoru, Watanabe, Satoshi, Tanaka, Hiroshi, Ito, Kazuhiko, Ishida, Takashi, Makino, Masato, Iwashima, Akira, Matsumoto, Naoya, Sato, Kazuhiro, Ichikawa, Kosuke, Abe, Tetsuya, Yoshizawa, Hirohisa, Kikuchi, Toshiaki
Publicado 2021

mTOR Inhibitors Control the Growth of EGFR Mutant Lung Cancer Even after Acquiring Resistance by HGF

por Ishikawa, Daisuke, Takeuchi, Shinji, Nakagawa, Takayuki, Sano, Takako, Nakade, Junya, Nanjo, Shigeki, Yamada, Tadaaki, Ebi, Hiromichi, Zhao, Lu, Yasumoto, Kazuo, Nakamura, Takahiro, Matsumoto, Kunio, Kagamu, Hiroshi, Yoshizawa, Hirohisa, Yano, Seiji
Publicado 2013

Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors

por Sato, Ko, Watanabe, Satoshi, Ohtsubo, Aya, Shoji, Satoshi, Ishikawa, Daisuke, Tanaka, Tomohiro, Nozaki, Koichiro, Kondo, Rie, Okajima, Masaaki, Miura, Satoru, Tanaka, Junta, Sakagami, Takuro, Koya, Toshiyuki, Kagamu, Hiroshi, Yoshizawa, Hirohisa, Narita, Ichiei
Publicado 2016

Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases

por Saida, Yu, Watanabe, Satoshi, Abe, Tetsuya, Shoji, Satoshi, Nozaki, Koichiro, Ichikawa, Kosuke, Kondo, Rie, Koyama, Kenichi, Miura, Satoru, Tanaka, Hiroshi, Okajima, Masaaki, Terada, Masaki, Ishida, Takashi, Tsukada, Hiroki, Makino, Masato, Iwashima, Akira, Sato, Kazuhiro, Matsumoto, Naoya, Yoshizawa, Hirohisa, Kikuchi, Toshiaki
Publicado 2019

Prognostic significance of the radiologic features of pneumonitis induced by anti‐PD‐1 therapy

por Watanabe, Satoshi, Ota, Takeshi, Hayashi, Masachika, Ishikawa, Hiroyuki, Otsubo, Aya, Shoji, Satoshi, Nozaki, Koichiro, Ichikawa, Kosuke, Kondo, Rie, Miyabayashi, Takao, Miura, Satoru, Tanaka, Hiroshi, Abe, Tetsuya, Okajima, Masaaki, Terada, Masaki, Ishida, Takashi, Iwashima, Akira, Sato, Kazuhiro, Yoshizawa, Hirohisa, Kikuchi, Toshiaki
Publicado 2020

Phase II study of nanoparticle albumin-bound paclitaxel monotherapy for relapsed non-small cell lung cancer with patient-reported outcomes (NLCTG1302)

por Shoji, Satoshi, Miura, Satoru, Watanabe, Satoshi, Ohtsubo, Aya, Nozaki, Koichiro, Saida, Yu, Ichikawa, Kosuke, Kondo, Rie, Tanaka, Tomohiro, Koyama, Kenichi, Tanaka, Hiroshi, Okajima, Masaaki, Abe, Tetsuya, Ota, Takeshi, Ishida, Takashi, Makino, Masato, Iwashima, Akira, Sato, Kazuhiro, Matsumoto, Naoya, Yoshizawa, Hirohisa, Kikuchi, Toshiaki
Publicado 2022

Transfer of in vitro-expanded naïve T cells after lymphodepletion enhances antitumor immunity through the induction of polyclonal antitumor effector T cells

por Tanaka, Tomohiro, Watanabe, Satoshi, Takahashi, Miho, Sato, Ko, Saida, Yu, Baba, Junko, Arita, Masashi, Sato, Miyuki, Ohtsubo, Aya, Shoji, Satoshi, Nozaki, Koichiro, Ichikawa, Kosuke, Kondo, Rie, Aoki, Nobumasa, Ohshima, Yasuyoshi, Sakagami, Takuro, Abe, Tetsuya, Moro, Hiroshi, Koya, Toshiyuki, Tanaka, Junta, Kagamu, Hiroshi, Yoshizawa, Hirohisa, Kikuchi, Toshiaki
Publicado 2017

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)

por Watanabe, Satoshi, Sakai, Kazuko, Matsumoto, Naoya, Koshio, Jun, Ishida, Akira, Abe, Tetsuya, Ishikawa, Daisuke, Tanaka, Tomohiro, Aoki, Ami, Kajiwara, Tomosue, Koyama, Kenichi, Miura, Satoru, Goto, Yuka, Sekiya, Tomoki, Suzuki, Ryo, Kushiro, Kohei, Fujisaki, Toshiya, Yanagimura, Naohiro, Ohtsubo, Aya, Shoji, Satoshi, Nozaki, Koichiro, Saida, Yu, Yoshizawa, Hirohisa, Nishio, Kazuto, Kikuchi, Toshiaki
Publicado 2022

Subsequent systemic therapy for non-small cell lung cancer patients with immune checkpoint inhibitor-related interstitial lung disease

por Sato, Yusuke, Watanabe, Satoshi, Ota, Takeshi, Kushiro, Kohei, Fujisaki, Toshiya, Takahashi, Miho, Ohtsubo, Aya, Shoji, Satoshi, Nozaki, Koichiro, Ichikawa, Kosuke, Hokari, Satoshi, Kondo, Rie, Hayashi, Masachika, Ishikawa, Hiroyuki, Miyabayashi, Takao, Abe, Tetsuya, Miura, Satoru, Tanaka, Hiroshi, Okajima, Masaaki, Terada, Masaki, Ishida, Takashi, Iwashima, Akira, Sato, Kazuhiro, Yoshizawa, Hirohisa, Aoki, Nobumasa, Ohshima, Yasuyoshi, Koya, Toshiyuki, Kikuchi, Toshiaki
Publicado 2021

The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events

por Fujisaki, Toshiya, Watanabe, Satoshi, Ota, Takeshi, Kushiro, Kohei, Sato, Yusuke, Takahashi, Miho, Ohtsubo, Aya, Shoji, Satoshi, Nozaki, Koichiro, Ichikawa, Kosuke, Hokari, Satoshi, Kondo, Rie, Miyabayashi, Takao, Abe, Tetsuya, Miura, Satoru, Tanaka, Hiroshi, Okajima, Masaaki, Terada, Masaki, Matsumoto, Naoya, Ishida, Takashi, Iwashima, Akira, Sato, Kazuhiro, Yoshizawa, Hirohisa, Aoki, Nobumasa, Hayashi, Masachika, Ohshima, Yasuyoshi, Koya, Toshiyuki, Kikuchi, Toshiaki
Publicado 2021